Back to Agenda
Session 18: FDA Review of Clinical Trial Data in an NDA or BLA
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
- This session will provide insights into the how and what of Agency pre-approval review of safety data from interventional clinical trials in marketing applications.
Have an account?